Quantitative Analysis of Neurocrine Biosciences, Inc. (XNAS:NBIX)

I recently bought Neurocrine Biosciences, Inc. (NASDAQ: $NBIX). As a disclosure, I consider this to be a highly speculative investment. Perform your own due diligence.

Snapshot for Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: System-Specific Biopharmaceuticals

Country: USA

Current Price: $96.03

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Financial Health for Neurocrine Biosciences, Inc.

Altman Z-Score: 9.64

Financial Health: SAFE

Revenue Analysis for Neurocrine Biosciences, Inc.

Regressed Revenue Growth: 34.70%

Based on historical valuations and revenue, the present value for Neurocrine Biosciences, Inc. is:

Bearish Case: $241.41

Bullish Case: $611.94

Income Analysis for Neurocrine Biosciences, Inc.

Regressed Net Income Growth: 29.85%

Based on historical valuations and net income, the present value for Neurocrine Biosciences, Inc. is:

Bearish Case: $84.37

Bullish Case: $6,399.89

Free Cash Flow Analysis for Neurocrine Biosciences, Inc.

Cost of Equity: 8.00%

Weighted Average Cost of Capital: 6.59%

Based on sensitivity analysis, the fair value for Neurocrine Biosciences, Inc. is:

Bearish Case: $118.78

Bullish Case: $180.02

Dividend Analysis for Neurocrine Biosciences, Inc.

Current Yield: 0.00%

Historical Yield: 0.00%

Based on historical dividends, the fair value for Neurocrine Biosciences, Inc. is: $0.00

Final Ratings for Neurocrine Biosciences, Inc.

Growth Rating: 5-Star

Income Rating: 1-Star